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Abstract
Background: The oncoprotein c-Myc has been intensely studied in breast cancer and mouse
mammary tumor models, but relatively little is known about the normal physiological role of c-Myc
in the mammary gland. Here we investigated functions of c-Myc during mouse mammary gland
development using a conditional knockout approach.
Results: Generation of c-mycfl/fl mice carrying the mammary gland-specific WAPiCre transgene
resulted in c-Myc loss in alveolar epithelial cells starting in mid-pregnancy. Three major phenotypes
were observed in glands of mutant mice. First, c-Myc-deficient alveolar cells had a slower
proliferative response at the start of pregnancy, causing a delay but not a block of alveolar
development. Second, while milk composition was comparable between wild type and mutant
animals, milk production was reduced in mutant glands, leading to slower pup weight-gain. Electron
microscopy and polysome fractionation revealed a general decrease in translational efficiency.
Furthermore, analysis of mRNA distribution along the polysome gradient demonstrated that this
effect was specific for mRNAs whose protein products are involved in milk synthesis. Moreover,
quantitative reverse transcription-polymerase chain reaction analysis revealed decreased levels of
ribosomal RNAs and ribosomal protein-encoding mRNAs in mutant glands. Third, using the
mammary transplantation technique to functionally identify alveolar progenitor cells, we observed
that the mutant epithelium has a reduced ability to repopulate the gland when transplanted into
NOD/SCID recipients.
Conclusion: We have demonstrated that c-Myc plays multiple roles in the mouse mammary gland
during pregnancy and lactation. c-Myc loss delayed, but did not block proliferation and
differentiation in pregnancy. During lactation, lower levels of ribosomal RNAs and proteins were
present and translation was generally decreased in mutant glands. Finally, the transplantation
studies suggest a role for c-Myc in progenitor cell proliferation and/or survival.
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Background
The oncoprotein c-Myc is a basic helix-loop-helix tran-
scription factor implicated in multiple cellular processes,
including proliferation, differentiation, metabolism, and
apoptosis (reviewed in Eilers and Eisenman [1]). c-Myc
regulates RNA polymerase II (Pol II) driven transcription
of a large set of targets [2-4] and has been reported to have
effects on global chromatin modification [5]. Further-
more, c-Myc stimulates RNA Pol I [6,7] and Pol III [8,9]
mediated transcription, thus linking it to ribosome bio-
genesis and translation. In addition, c-Myc has been
implicated in mitochondrial biogenesis [10] and global
miRNA expression [11]. Recently, non-transcriptional
effects of c-Myc on DNA replication [12] and translation
progression [13] have also been described.
Deregulated levels of c-Myc, resulting from amplification,
translocation, transcriptional, translational as well as
other mechanisms have been observed in numerous
human tumors (reviewed in Vita and Henriksson [14]). In
breast cancer, c-Myc overexpression occurs in >50% of pri-
mary tumors [15] and has been reported to correlate with
poor prognosis [16]. The use of transgenic mouse models
has helped to analyze c-Myc-induced mammary tumori-
genesis [17-19], but little is known about the normal
physiological function of c-Myc in the mammary gland.
A number of studies have described different roles for c-
Myc in other organs. The full knockout of c-Myc is embry-
onic lethal [20,21], due to its indispensable function in
the placenta and the hematopoietic system [22,23]. Sev-
eral conditional mouse models expressing Cre recombi-
nase under different promoters have been generated in
order to delete c-Myc in skin [24,25], liver [3,26,27], pan-
creas [28,29], intestines [30,31], and bone marrow [32-
34]. Taken together, the results revealed various organ-
specific roles for c-Myc in controlling development and
regeneration, cell size or number and stem cell differenti-
ation and maintenance. Each report is of interest, not only
for deciphering physiological functions of c-Myc, but also
when considering c-Myc as a therapeutic target in human
cancer.
The mammary gland is a convenient model for develop-
mental studies, as it goes through repeated cycles of pro-
liferation, differentiation and apoptosis during puberty
and pregnancy. The gland of a mature virgin female con-
sists of two compartments, a ductal epithelial network
and the stroma or mammary fat pad. Upon hormonal
stimulation in pregnancy, bursts of proliferation followed
by differentiation allow the gland to convert into a milk-
synthesizing machine. To study the role of c-Myc in the
mammary gland, a conditional approach using the Cre-
loxP system was employed. Whey acidic protein
(WAP)iCre transgenic mice were used to recombine the
LoxP-flanked c-myc locus in luminal alveolar cells starting
at mid-pregnancy and throughout lactation. Following
loss of c-Myc in the mammary gland, three main pheno-
types were observed. At the start of pregnancy, c-Myc-defi-
cient alveolar cells were impeded in their proliferative
response resulting in a delayed ability to differentiate.
Moreover, mutant glands displayed lower expression lev-
els of ribosomal RNA and proteins as well as a general
decrease in translation. Finally, the mutant mammary epi-
thelium had a reduced ability to grow when transplanted
into mammary fat pads. These results suggest that c-Myc
has multiple roles in the mammary gland, affecting prolif-
eration, biosynthetic capacity, and progenitor cell prolif-
eration and/or survival.
Results
WAPiCre-mediated ablation of c-Myc in the mammary 
gland
To study the role of c-Myc in mammary gland develop-
ment, we used a conditional approach, crossing c-mycfl/fl
mice [21] to WAPiCre transgenic mice [35]. The generated
offspring will be referred to as wild type (WT, c-mycfl/
fl;WAPiCre- or c-mycfl/+; WAPiCre-), heterozygous (c-mycfl/
+;WAPiCre+) and mutant (c-mycfl/fl;WAPiCre+) mice. In
animals positive for the WAPiCre transgene, the complete
open reading frame of c-myc  will be excised upon Cre
expression (Figure 1(a)). To assess onset and extent of
WAPiCre expression, we performed immunohistochemis-
try (IHC) against Cre recombinase on sections from
mutant mammary glands (Figure 1(b)). Cre expression
was first detected at day 14.5 of pregnancy in scattered
luminal alveolar cells. The number of Cre-expressing cells
increased continuously until after parturition, when posi-
tive staining for Cre was seen in essentially all luminal
cells. To monitor recombination, we performed polymer-
ase chain reaction (PCR) on genomic DNA isolated from
mammary glands at different developmental stages. The
220 base pair band, indicating the presence of the recom-
bined allele, was first detected at day 14.5 of pregnancy
(Figure 1(c)), consistent with the results from IHC. Start-
ing then, levels of c-myc  mRNA decreased rapidly in
glands of mutant mothers and were essentially undetecta-
ble throughout lactation (Figure 1(d)). With the commer-
cially available antibodies, it has not been possible to
detect c-Myc in the lactating mammary gland by IHC
(data not shown; Klinakis et al. [36]). Since the half-life of
c-Myc protein and mRNA is short [37], it is likely that
mutant glands have little or no c-Myc by the onset of lac-
tation. Finally, mRNA levels of the cell cycle inhibitor
p21Cip1, a well-studied target of c-Myc-mediated repres-
sion [38,39], were upregulated in c-Myc-deficient glands
during lactation (Figure 1(e)), which is in agreement with
the functional loss of c-Myc in mutant glands.BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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Targeted disruption of c-Myc in the mammary gland Figure 1
Targeted disruption of c-Myc in the mammary gland. (a) Schematic diagram of c-myc floxed allele and recombined 
allele after Cre-mediated excision of floxed region. The position of the 220 base pair (bp) polymerase chain reaction (PCR) 
product for detecting recombined allele is indicated. (b) Immunohistochemistry against Cre (brown nuclei) on paraffin sections 
of mutant mammary glands. Representative staining from different stages of pregnancy (P), lactation (L), and involution (I). Scale 
bar, 100 μm. (c) PCR on genomic DNA from glands taken at the indicated days from wild type (WT) (W) and mutant (M) mice 
to detect the recombined c-myc allele (220 bp) indicated in (a). (d) Semi-quantitative reverse transcription-PCR showing c-myc 
and β-actin mRNA levels in glands of WT and mutant mice removed at two time points during a first pregnancy and at seven 
times in lactation. (e) Relative expression levels of p21Cip1 determined by qPCR in WT and mutant glands at four different time 
points in lactation. Results are the average of duplicate measurements with β-actin mRNA levels as reference.
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c-Myc mutant mothers display a lactation defect with less 
efficient milk production
Monitoring survival and weight of newborn pups is rou-
tinely used as a measure of lactation [40]. Thus, we per-
formed a pup weight analysis to examine the efficiency of
milk production in WT and mutant females. Growth
curves generated from seven foster pups per mother
showed that pups nursed by mutant mothers grew signif-
icantly slower compared with pups nursed by a WT
mother (Figure 2(a), left panel). However, when compar-
ing a mutant mother nursing only two foster pups to a WT
mother nursing six pups, there was no significant differ-
ence in pup body weight (Figure 2(a), right panel). This
suggests that milk quantity, but not quality might be
affected in c-Myc-deficient glands.
To test this hypothesis, we first examined milk composi-
tion. Milk samples taken from WT and mutant mothers at
day 14.5 and 15.5 of lactation were analyzed for protein,
lactose and fat content, the three major milk components.
On a Coomassie stained gel, milk protein pattern and
concentration were identical in equal volumes of milk
from WT and mutant mothers (Figure 2(b), caseins are
indicated) (see also Marte et al. [41]). Furthermore, the
concentration of lactose, the major carbohydrate and
osmole in milk, as well as the fat content were determined
in milk samples from a group of five animals made up of
WT, heterozygous (showing no overt phenotype) and
mutant mothers (Figure 2(c) and 2(d)). Lactose concen-
tration was determined in a colorimetric assay on skim
milk samples, whereas fat content was measured as the
ratio of cream layer length over total milk length after cen-
trifugation ('creamatocrit') (Lucas et al. [42]). While one
heterozygous mother showed a slightly decreased lactose
concentration, likely due to natural variation (Figure
2(c)), there were no consistent alterations in either lactose
or fat content within the samples.
Next, to compare the approximate amount of milk pro-
duced in the lactating glands from WT and mutant moth-
ers, the following experiment was performed. In the first
setting, mothers were sacrificed immediately after remov-
ing them from their actively suckling pups. In the second
setting, mothers were removed from their pups and sacri-
ficed 2 hours later, which allows the glands to fill with
milk. When comparing high magnifications of whole
mount preparations taken from actively nursing mothers,
glands from WT and mutant mice looked nearly identical
(Figure 2(e), panels a and b). However, only the WT
females showed clear signs of milk-filling, displaying
large, distended alvoeli after 2 hours without pups (Figure
2(e), panel c, arrows), while glands of mutant mothers
appeared only slightly distended (Figure 2(e), panel d).
Finally, we examined the milk proteins via a Western anal-
ysis carried out on protein lysates made from lactating
mammary glands of WT and mutant mothers. Equal
amounts of protein were loaded and membranes probed
with a rabbit anti-milk serum [41], producing a staining
pattern of multiple milk proteins (Figure 2(f)). The blot
shows that mutant protein lysates contain less milk protein
than the corresponding WT lysate at day 5.5, 10.5, and 15.5
of lactation. The level of α-tubulin, used as a loading con-
trol, was the same in each paired WT and mutant sample.
Taken together, these results clearly suggest that the
reduced nursing ability in c-Myc mutant mothers is due to
decreased or slower milk production, while milk composi-
tion is essentially the same in mutant and WT mothers.
Alterations in alveolar density and secretory activity
To analyze the lactation defect in more detail, we investi-
gated the morphology of glands from lactating, actively
nursing WT and mutant mothers via IHC. Cytokeratin
(CK) 18-stained cross-sections were scanned (Figure
3(a)), revealing that mutant glands contained more
unstained stromal area than WT glands. To obtain quanti-
tative results, the area covered by alveoli (including epi-
thelium and lumen) was measured and the ratio of
alveolar area over total organ area was calculated (Figure
3(b)), revealing that alveolar area in mutant glands was
significantly decreased, on average by 30% (lactation day
3.5) and 20% (lactation day 10.5). Interestingly, the
number of alveoli per organ area was not altered (Figure
3(c)), suggesting that in mutant glands there is a reduc-
tion in the size of alveoli, which could be due to smaller
and/or fewer alveolar cells or less milk, even in an active
nursing state.
To analyze this in more detail, proliferation and apoptosis
were investigated in lactating glands. We did not detect
any difference in BrdU incorporation between WT and
mutant glands (data not shown), nor were shed cells
apparent in the lumens (for example, when looking at
high magnifications of Figures 1(b) and 3(a)), suggesting
no dramatic alterations in cell number. Thus, we exam-
ined the glands via electron microscopy to look directly at
the secretory activity of alveolar cells. The endoplasmic
reticulum forms highly organized, parallel strands, from
which secretory vesicles bud to fuse into the alveolar
lumen (Figure 3(d)). When comparing day 7.5 lactating
WT and mutant glands, mutant cells are dominated by
parallel regions of thin regular endoplasmic reticulum. In
contrast, WT cells contain more dilated reticulum and
budding vesicles (arrows), indicating high protein synthe-
sis activity. The result was confirmed in two pairs of day
4.5 lactating mice (not shown). The non-dilated endo-
plasmic reticulum in c-Myc mutant glands suggests a
defect in protein synthesis, at the cellular level.
c-Myc controls biosynthetic activity in the mammary gland
The previous results suggest that c-Myc loss in alveolar
cells might cause a general defect in milk production,BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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Ablation of c-Myc in mammary glands results in impaired lactation due to reduced milk volume Figure 2
Ablation of c-Myc in mammary glands results in impaired lactation due to reduced milk volume. (a) Growth 
analysis of pups nursed by wild type (WT) or mutant mothers. Data are shown as average body weight plus standard deviation. 
Left panel: analysis of three littermate mothers nursing seven WT pups each. *, P = 2.2 × 10-5; **, P = 1.1 × 10-9. Right panel: 
comparison of a WT mother with six pups to a mutant mother nursing two pups (all pups WT littermates). NS = not signifi-
cant, P = 0.52. (b) Milk protein composition in milk obtained from WT (W) or mutant (M) mice at lactation day 15.5. Freshly 
collected milk was diluted 1:20 in phosphate-buffered saline and 5 or 10 μl loaded on a 15% SDS-gel for Coomassie staining. 
(c) Measurement of lactose concentration in milk collected at lactation day 14.5. In a colorimetric assay, lactose concentration 
is determined as concentration of free galactose in lactase-treated skim milk. Results from five animals with the indicated gen-
otype are shown as average value of duplicate measurements. (d) Analysis of fat content in the same milk samples used in (c), 
presented as percentage of fat layer length over total length of milk. Results are the mean ± standard deviation of three meas-
urements per animal. (e) Whole mounts of WT and mutant mammary glands collected on lactation day 0.5. Mothers were sac-
rificed directly after removing them from pups (a, b), or after 2 hours without pups to allow filling of glands with milk (c, d). 
Arrows point to distended alveoli in WT gland. Scale bar, 500 μm. (f) Western analysis of milk proteins (loading: 1 μg per lane) 
and α-tubulin (loading: 9 μg per lane of the identical lysates) of WT and mutant mammary gland lysates at lactation day 5.5, 
10.5, and 15.5. Blot was probed with anti-milk serum; two different exposure times are shown.
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including milk components and the enzymes involved in
their synthesis. This was analyzed in more detail, first by
examining mRNA levels of milk proteins and enzymes
that are strongly upregulated in lactating mammary
glands [43,44]. Transcripts encoding: α-lactalbumin
(Lalba) and β-casein (Csn2), both milk proteins, the
former also the rate-limiting co-factor for lactose synthesis
[45], as well as Δ6 fatty acid desaturase 2 (Fads2), stearoyl-
CoA desaturase 2 (Scd2), elongation of very long chain
fatty acids (Elovl1), and aldolase C (Aldo3), enzymes
involved in lipid synthesis [44], were measured by semi-
quantitative reverse transcription (RT)-PCR. All tran-
scripts were expressed at comparable levels in WT and
mutant glands analyzed between lactation day 2.5 and
10.5 (Figure 4(a)), including Fads2, Scd2 and Elovl1 that
are described Myc targets in other systems (http://
www.myc-cancer-gene.org/index.asp, Zeller et al. [46]).
This suggests that regulation of milk production by c-Myc
might occur by a non-transcriptional mechanism.
Next we investigated mRNA translation in WT and mutant
glands by performing polysome fractionation on mam-
mary gland lysates obtained at lactation day 4.5. This tech-
nique allows the separation of mRNAs along a sucrose
gradient depending on their ribosomal load. When over-
laying profiles from WT and mutant glands according to
their monosome peaks, a change in the average size of
polysomes was evident in c-Myc deficient glands, with the
peak being shifted to smaller polysomes (Figure 4(b),
upper panel). Results from one pair of WT and mutant
animals are shown; three additional pairs of animals were
examined, yielding similar results (data not shown). As a
control, we performed polysome fractionations on livers
obtained from the females used for generating the mam-
mary gland profiles. WT and mutant mice retain c-Myc in
the liver since WAPiCre is not expressed there. The polys-
ome distribution from livers of WT and mutant females
was nearly identical (Figure 4(b), lower panel), showing
that the altered polysome distribution is specific for c-
Myc-deficient mammary glands. These results suggest that
there is a general reduction in translation efficiency in
mammary glands in the absence of c-Myc.
In addition to Pol II targets, c-Myc controls Pol I-mediated
rRNA and Pol III-mediated tRNA and 5S rRNA transcription,
thereby regulating cellular physiology at multiple levels
[1,47-49]. Accordingly, we analyzed a panel of Pol I, II and
III c-Myc targets implicated in ribosome biogenesis and
translation. The results from qPCR are displayed as relative
expression levels in mutant mice, compared with matched
WT littermates; the data are from two pairs of mice at the
indicated times in lactation (Table 1). mRNAs encoding
nucleolin and nucleophosmin, which are involved in ribos-
ome biogenesis, mRNAs encoding large and small ribos-
omal subunit proteins, and the mRNA for poly(A)-binding
protein1 (PABPC1), involved in translation, all showed a
decrease in samples from mutant females. In particular, the
ribosomal protein encoding mRNAs were strongly affected,
frequently being more than two-fold downregulated in c-
Myc-deficient glands (Table 1, values below 0.50). Further-
more, the levels of 5S rRNA as well as the rapidly processed
5'-external transcribed spacer of the 45S rRNA precursor [7],
were generally lower in c-Myc mutant glands. This suggests
that the decreased translation efficiency in c-Myc mutant
glands is due to a general impairment of ribosome biogen-
esis and translation.
Finally, we examined the translational efficiency, that is,
ribosomal load, of specific mRNAs using RNA isolated
from each fraction of the polysome gradient. The mRNAs
encoding Lalba, Csn2, Fads2, Scd2, Elovl1 and Aldo3 each
shifted to smaller polysomes, with the peaks in fractions 7
to 9 in mutant versus 8 to 10 in WT glands (Figure 4(c),
upper panel, open arrow heads). Interestingly, while each
of these transcripts is expressed to the same level in WT
and mutant mammary glands (Figure 4(a)), this shift
clearly shows that they are less efficiently translated. In
contrast to the mRNAs encoding proteins directly
involved in milk production, the mRNA distribution of β-
actin, CK18 and GAPDH along the polysome gradients
was essentially the same in WT and mutant glands (Figure
4(c), lower panel, open arrow heads). To confirm that the
observed reduced translation efficiency results in less pro-
tein production in mutant glands, we performed a West-
ern analysis for β-casein on mammary gland lysates
(Figure 4(d)). Compared with the α-tubulin loading con-
trol, there is a clear reduction in casein levels in lysates of
mutants compared with WT littermates. Taken together,
these results show that a reduction in translation effi-
ciency is likely to be responsible for slower milk produc-
tion in c-Myc mutant glands.
Delayed proliferative response in c-Myc mutant mammary 
glands
c-Myc loss has an effect on cell cycle progression and pro-
liferation in many organs [25,28,29,31,33]. Thus, we
investigated if c-Myc loss affects proliferation during preg-
nancy. The WAPiCre model is particularly suited for stud-
ying proliferation in a second pregnancy since a
population of WAPiCre expressing cells does not undergo
a secretory fate, but survives lactation and involution.
These cells are termed Pi-MECs (for parity-identified
mammary epithelial cells) (see also Smith and Medina
[50]) and function as progenitor cells for epithelium-
forming alveolar structures during ensuing rounds of
pregnancy and lactation [51,52]. In our model, cells in c-
mycfl/fl;WAPiCre+ mice that survive involution will have
lost c-Myc due to Cre expression during the first preg-
nancy. Consistent with these characteristics, the recom-
bined c-myc allele was detected in non-pregnant, parous
females, and in all stages of a second pregnancy (Figure
5(a)), in contrast to the first pregnancy where recombina-BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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Alterations in alveolar density and secretory activity Figure 3
Alterations in alveolar density and secretory activity. (a) Immunohistochemistry against cytokeratin (CK) 18 on sec-
tions of wild type (WT) and mutant glands to visualize epithelium (brown). For optimal comparison, a central part of each gland 
containing the lymph node was taken. Lymph nodes (blue) and stroma display no CK18 staining. (b) Quantification of alveolar 
area per total organ area (excluding lymph node) from sections processed as shown in (a). Two sections per animal were quan-
tified and the average was used for calculations. Results are the mean ± standard deviation of four and three pairs of animals 
quantified on lactation day 3.5 and 10.5, respectively. *, P = 0.00057; **, P = 0.0043. (c) Number of alveoli (including mean ± 
standard deviation) measured in four pairs of animals at lactation day 3.5, which were used for area measurement in (b). Num-
bers were calculated per analyzed area, and values from WT glands were set to 1. NS = not significant, P = 0.25. (d) Electron 
microscopy pictures from day 7.5 lactating WT and mutant glands. Arrows point to regions of dilated, vesicle forming endo-
plasmic reticulum. Scale bar, 500 nm.
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tion was first detectable at day 14.5 (Figure 1(c)). Further-
more, c-myc mRNA levels are very low during a second
pregnancy and lactation in mutant, compared with WT
glands (Figure 5(b)).
In the normal mammary gland c-myc mRNA is highest
between day 6.5 and day 12.5 of pregnancy then drops to
baseline for the remainder of pregnancy and throughout
lactation [53]. In our model, during the first pregnancy
Cre activity, hence c-Myc deletion is maximal early in lac-
tation, a time when it has not been possible to detect c-
Myc by IHC (data not shown; Klinakis et al. [36]). How-
ever, since the recombined c-myc allele was detected in all
stages of a second pregnancy (Figure 5(a)) and c-myc
mRNA levels are very low in mutant glands (Figure 5(b)),
we performed IHC staining for c-Myc on sections pre-
pared from second pregnancy day 6.5 mammary glands.
c-Myc staining was evident in sections prepared from WT
females (see Additional file 1), although not as strong as
the day 10.5 embryonic liver positive control [22]. In con-
trast, in the mutant glands, c-Myc staining was absent in
most of the epithelial clusters. These results clearly show
that in c-mycfl/fl;WAPiCre+mice c-Myc mRNA and protein
are lost.
To monitor proliferation during pregnancy, IHC for Ki-
67, which stains all but G0 cells, was performed (Figure
5(c), left). Furthermore, cyclin D1, which is preferentially
expressed in the mammary gland and is essential for pro-
liferation [54] was analyzed by IHC (Figure 5(c), right). In
sections from WT glands the majority of cells were actively
cycling at pregnancy day 6.5, displaying positive Ki-67
staining, as well as high levels of cyclin D1. In striking
contrast, in mutant glands analyzed on the same day, the
majority of cells were Ki-67 negative, and had low or
undetectable cyclin D1, showing that most cells were not
proliferating. By pregnancy day 14.5, however, the major-
ity of mutant cells were cycling, showing that the slower
proliferative response was surmountable. Mutant glands
at day 14.5 resembled WT glands at day 6.5, whereas by
day 14.5, WT glands displayed advanced development
with many lumen-forming, alveolar clusters. Of note, lev-
els of N-myc and L-myc were the same as in WT glands,
showing that there was no compensation at the mRNA
level in glands lacking c-Myc (Figure 5(d)). In summary,
the results indicate that in the absence of c-Myc, alveolar
cells show a delayed proliferative response at the start of
pregnancy.
Delayed, but successful differentiation in c-Myc mutant 
glands
The slower proliferation in the mutant glands resulted in
delayed differentiation, which was monitored by IHC
against milk proteins (Figure 6(a)). While the WT gland at
pregnancy day 14.5 was producing milk, as shown by the
milk-filled lumen of the alveoli, the small alveolar clusters
in the mutant gland were essentially empty and no milk
was detected. By pregnancy day 16.5, however, alveoli
occasionally contained cytoplasmic lipid droplets (Figure
6(a), red circles, insert), indicating that the mutant cells
had begun differentiation and milk production. Indeed,
despite the delay in development, milk production was
successful since mutant mothers were able to nurse their
pups after parturition, albeit with pups showing reduced
body weight (data not shown). Interestingly, expression
of the WAPiCre transgene was also delayed in a second
pregnancy (Figure 6(b)). A control female (c-Mycfl/+;WAP-
iCre+) in its second pregnancy and lactation showed scat-
tered Cre staining at pregnancy day 16.5 and ubiquitous
staining at lactation day 3.5 (as in Figure 1(b)). In con-
trast, mutant glands displayed almost no Cre-expressing
cells at day 16.5 of a second pregnancy and only scattered
positive cells at lactation day 3.5. Importantly, at day 10.5
of the second lactation, the mutant glands showed ubiq-
uitous Cre expression, indicating that the transgene had
not been silenced (Figure 6(b)). These results suggest that
in the c-Myc mutant glands the WAPiCre transgene and
endogenous milk protein genes show a similar delay in
their expression pattern, very likely reflecting the slower
proliferative response.
Finally, quantification of the alveolar density showed that
during a second round of pregnancy and lactation, c-Myc
mutant glands displayed a strongly reduced alveolar area
(Figure 6(c)). With more than a 40% reduction on lacta-
tion day 3.5, this effect is more severe than the 30%
decrease observed in a first pregnancy (Figure 3(b)). The
reduced alveolar area is also evident in whole mount
preparations from WT and mutant females obtained at the
same time points (Figure 6(d)). The results might be
explained, in part, by the slower proliferation leading to
an incomplete alveolar expansion in the mutant glands
(Figure 5(c)). In conclusion, the data suggest that c-Myc is
dispensable for secretory differentiation, however, due to
slower proliferation there is also a delay in differentiation
in c-Myc mutant mammary glands.
Effects on progenitor cells in c-Myc mutant glands
Considering the more severe phenotype in the second
pregnancy, we performed additional experiments to
investigate the role of c-Myc in mammary progenitor cells.
A quantification of the alveolar number from three pairs
of WT and mutant females, analyzed at lactation day 3.5
of a second pregnancy, revealed a significant reduction in
c-Myc mutant glands (Figure 7(a)), suggesting that
mutant glands start the second pregnancy with fewer alve-
olar progenitor cells. Importantly, there was no difference
in the alveolar number between WT and mutant glands
measured at the first lactation (Figure 3(c)).
To functionally investigate mammary progenitor cells, we
performed reconstitution experiments into cleared mam-BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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Altered translation efficiency in mutant mammary glands Figure 4
Altered translation efficiency in mutant mammary glands. (a) Semi-quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) on α-lactalbumin (Lalba), β-casein (Csn2), Δ6 fatty acid desaturase 2 (Fads2), stearoyl-CoA desaturase 2 
(Scd2), elongation of very long chain fatty acids (Elovl1), aldolase C (Aldo3) and β-actin (Actb) in wild type (WT) (W) and mutant (M) 
glands taken at different time points during lactation. (b) Polysome profiles of day 4.5 lactating mammary glands (upper panel) 
and corresponding livers (lower panel) of the same animals. Profiles were overlaid according to their 80S peak. Hollow arrow-
heads mark the peaks of the polysomal fractions. (c) Semi-quantitative RT-PCR on mRNA isolated from the indicated gradient 
fractions from WT and mutant polysomes. mRNA distribution analyzed for genes described in (a) (upper panel) and 'control 
genes' β-actin, CK18, and GAPDH (lower panel). Hollow arrowheads indicate the peak of each mRNA distribution along the gra-
dient. (d) Western analysis of β-casein (loading: 0.25 μg per lane) and α-tubulin (loading: 50 μg per lane of the identical lysates) 
on WT and mutant mammary gland lysates obtained at three time points in lactation.
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mary fat pads. Pieces of mammary glands from WT and
mutant mothers were transplanted into NOD/SCID recip-
ients. Donor glands were taken from lactation day 5.5, a
time point when Cre activity is maximal and most cells
will have lost c-Myc. Recipients were sacrificed after 8
weeks in order to examine survival and outgrowth poten-
tial of mammary progenitor cells. The results from two
independent experiments are summarized in Figure 7(b).
Epithelium from WT donors reconstituted a ductal net-
work in all recipients. A representative outgrowth that
filled around 30% of the gland ('+ +') is shown in Figure
7(c). In contrast, in 60% of the cases, transplanted epithe-
lium from mutant donors failed to grow out and only
rudimentary ductal trees were detected in the recipients
(Figure 7(c), mutant, left panel). In the cases when
mutant epithelium formed ductal outgrowths (Figure
7(c), mutant, right panel), these were similar to those
formed by WT epithelium. A PCR analysis showed that
the recombined allele could be detected in DNA recovered
from two positive ('+ +') mutant outgrowths (Figure
7(d)), showing that c-Myc-deficient epithelial cells sur-
vived and likely contributed to outgrowth formation. In
conclusion this suggests that c-Myc has an impact on
mammary gland progenitor cell survival and/or prolifera-
tion.
Discussion
Since the early 1980s, numerous investigations focused
on c-Myc, exploring its role in normal organ physiology,
as well as in tumor biology (for recent reviews see Eilers
and Eisenman [1], Meyer and Penn [55]). Results from
mammary gland transgenic models implicate c-Myc with
lineage commitment during embryonic development
[56], with precocious proliferation and differentiation
during pregnancy [57], and with premature involution
[58]. c-Myc has also been intensely studied in breast can-
cer [16,59,60], and in mouse models of mammary cancer
[17-19]. Here we present for the first time physiological
functions of c-Myc during mammary gland development
using a conditional knockout approach. Given the ability
of c-Myc to regulate transcription of a large number of
genes, thereby impacting on all aspects of cellular physiol-
ogy, it is not surprising that loss of c-Myc in the mammary
gland affects different processes. We observed strong phe-
notypes at the start of pregnancy and during lactation;
whereas during involution no alterations in the c-Myc
mutant glands were observed (data not shown). At the
Table 1: Levels of c-Myc targets involved in ribosome biogenesis and translation
Targets Relative expressiona
L2.5 L5.5
Mu-1 Mu-2 Mu-3 Mu-4
RNA Pol II productsb
Nucleolar proteins
Nucleophosmin 0.62 0.78 0.59 0.39
Nucleolin 0.58 0.93 0.65 0.26
Large ribosomal proteins
L3 0.47 0.77 0.40 0.24
L6 0.56 1.08 0.44 0.32
L11 0.62 0.97 0.37 0.33
L23 0.73 0.59 0.36 0.25
Small ribosomal proteins
S3 0.46 0.55 0.60 0.22
S19 0.49 0.83 0.45 0.18
Other
Poly(A)-binding protein 0.60 0.73 0.74 0.56
RNA Pol I product
5'-external transcribed spacer of 45S pre-rRNA 0.53 1.19 0.29 0.79
RNA Pol III product
5S rRNA 3.08 0.41 0.28 0.38
aResults are relative expression levels in mutant mice compared with levels in the corresponding wild type (WT) littermates. Four mutant mice 
(Mu-1 to -4) were analyzed on lactation day 2.5 and 5.5 and each value is relative to the matched WT value. bDirect targets of transcription 
activated by c-Myc, chosen from http://www.myc-cancer-gene.org/index.asp [46].BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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start of pregnancy, c-Myc-deficient alveolar cells were
impeded in their proliferative response, resulting in a
delayed ability to differentiate. Moreover, mutant glands
displayed slower milk production, a general decrease in
translation and reduced expression levels of ribosomal
RNA and proteins. Finally, the mutant mammary epithe-
lium had a reduced ability to grow when transplanted into
mammary fat pads suggesting that c-Myc has a role in pro-
genitor cell proliferation and/or survival.
Role of c-Myc in proliferation at pregnancy
Pregnancy is a time of intense cell division, and c-Myc lev-
els increase early in this developmental phase (our obser-
vations; Master et al. [53]). Indeed, cells from WT females
are essentially all cycling, showing high levels of cyclin D1
early in pregnancy. In contrast, c-Myc-deficient alveolar
cells remained in G0, displaying lower levels of cyclin D1,
and were delayed by at least 6 days in their proliferation.
The extensive alveolar development occurring during the
first half of pregnancy is dominated by progesterone (for
Delayed proliferative response of c-Myc mutant cells in second pregnancy Figure 5
Delayed proliferative response of c-Myc mutant cells in second pregnancy. (a) Detection of recombined allele in 
mutant glands as described in Figure 1(c). np = non-pregnant, parous. (b) Semi-quantitative reverse transcription-polymerase 
chain reaction (RT-PCR) on c-myc and β-actin as described in Figure 1(d). (c) Immunohistochemistry for Ki-67 (left) and cyclin 
D1 (right) on wild type (WT) and mutant glands taken at day 6.5 and 14.5 of a second pregnancy. Ki-67 stains all actively cycling 
cells (brown), resting cells in G0 are counterstained (blue). Scale bar, 100 μm. (d) Expression levels of N- and L-myc deter-
mined via semi-quantitative RT-PCR.
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reviews see Naidu et al. [61], Neville et al. [62]) and c-Myc
might have a role in mediating the response to this steroid
hormone. In breast cancer models, progesterone induces
c-Myc expression [63] via a progesterone receptor regula-
tory element upstream of c-myc [64]. c-Myc has a well-
described role in cell growth and proliferation [1]. Thus,
one mechanism underlying the slower proliferation
might be related to the established role of c-Myc in con-
trolling expression of cell cycle regulators [65], and pro-
gesterone might be the upstream regulator of c-Myc.
Moreover, c-Myc effects on proliferation might be more
indirect by regulating production of paracrine factors,
many of which have been shown to be required during
alveolar development (see, for example, Naidu et al. [61]).
It should also be mentioned that since this phenotype was
observed in the second pregnancy, it might result from a
Delayed differentiation of c-Myc mutant glands in a second pregnancy Figure 6
Delayed differentiation of c-Myc mutant glands in a second pregnancy. (a) Immunohistochemistry (IHC) against 
mouse milk in glands taken from wild type (WT) and mutant mice at second pregnancy day 14.5 and 16.5. Milk proteins are 
stained in brown, lipid droplets in the magnification are circled in red. Scale bar, 20 μm. (b) IHC against Cre on heterozygous 
and mutant glands taken at the indicated time points of a second pregnancy and lactation as described in Figure 1(b). Scale bar, 
100 μm. (c) Quantification of alveolar area in glands as described in Figure 2(c). Three and two pairs of animals (two sections 
per animal) were quantified at second pregnancy day 16.5 and lactation day 3.5, respectively. *, P = 0.0082; **, P = 0.013. (d) 
Whole mounts of WT and mutant mice at second pregnancy day 16.5 and lactation day 3.5. Scale bar, 1 mm.
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secondary effect of reduced translation and biosynthetic
activity during preceding developmental stages. While c-
Myc has been described to couple cell growth to cell divi-
sion [66], the question whether the observed effect in the
mammary gland is secondary or intrinsic to c-Myc loss,
can be better addressed with alternative Cre models.
During the second half of pregnancy, c-Myc-deficient cells
were proliferating and the mutant gland did 'catch up'
with the WT, as attested to by the ability of mutant moth-
ers to nurse. That this alveolar development is due to c-
Myc-proficient 'escaper' cells is very unlikely, since at preg-
nancy day 14.5 c-Myc levels are still very low while Cre
expression and recombination only re-starts at day 16.5.
An obvious reason explaining this phenotype might be a
slow compensation for c-Myc loss by other Myc family
members, since they are, in part, functionally redundant
to c-Myc [22,33]. While this cannot be ruled out, there
was no observable increase in L-myc or N-myc expression
at day 14.5 of pregnancy, a time point when mutant cells
were dividing. While we can only speculate, it is possible
that this developmental stage proceeds independently of
c-Myc. Indeed, the second half of pregnancy is controlled
by ligands activating prolactin receptor signaling [62], and
the Elf5 transcription factor was shown to be a key medi-
ator of prolactin receptor signaling in promoting alveolar
development [67]. Thus, we propose a model whereby c-
Myc is required early in pregnancy, potentially down-
Effects on mammary progenitor cells Figure 7
Effects on mammary progenitor cells. (a) Number of alveoli (including mean ± standard deviation) measured in three 
pairs of animals at second lactation day 3.5, which were used for area measurement in Figure 6(c). Numbers were calculated 
per analyzed area, and values from wild type (WT) glands were set as 1. *, P = 0.018. (b) Summary of two transplantation 
experiments with a total of 10 NOD/SCID mice grafted contralaterally with WT and mutant epithelium. Positive outgrowths 
were classified as '+' (filling <25% of cleared gland), '+ +' (filling 25% to 50%) or '+ + +' (filling about 75%). (c) Wild type: whole 
mount of virgin recipient gland containing a '+ +' outgrowth from transplanted WT epithelium, 8 weeks after transplantation. 
Mutants: whole mounts of a negative and a positive ('+ +') outgrowth obtained from mutant epithelium (left and right panel, 
respectively). Scale bar, 1 mm. (d) Polymerase chain reaction for the recombined allele as described in Figures 1(c) and 5(a), 
performed on DNA isolated from two recipient mice bearing WT (W) and positive ('+ +') mutant (M) outgrowths. Control: 
lactating mutant control; R-1, R-2: NOD/SCID recipient 1 and 2.
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stream of progesterone signaling, but is dispensable for
alveologenesis during the second half of pregnancy.
Role of c-Myc in translation during lactation
We also studied the role of c-Myc during lactation, when
the gland devotes its energy to the coordinately regulated
process of milk production. mRNAs encoding various
milk proteins and enzymes that are strongly upregulated
during lactation [43,44] were found at similar levels in
WT and mutant mammary glands, suggesting that loss of
c-Myc does not impair their transcription. Furthermore,
milk produced by the mutant glands is identical in com-
position to that made in control glands and pups were
healthy, albeit with a slower weight-gain when nursing on
mutant mothers. This phenotype, suggesting that there
was a slower rate of milk production in the mutant glands
was investigated and shown to result from a general
decrease in translation efficiency.
Numerous studies have described c-Myc's multifaceted
roles in mRNA translation, either via transcriptional [48]
or non-transcriptional mechanisms [13]. Our results
show that c-Myc controls transcription of various target
genes with important roles in translation. The c-Myc
mutant glands displayed lower levels of mRNA encoding
PABPC1, which is involved in translation initiation, and
mRNAs encoding nucleophosmin and nucleolin, both
involved in ribosome biogenesis. Interestingly, c-Myc loss
in intestinal crypts also led to reduced biosynthetic activ-
ity, characterized by a loss of nucleolar organizing regions
and decreased expression of nucleophosmin [31]. Moreo-
ver, very compelling results showing c-Myc's importance
during lactation arose from our examination of ribosomal
RNAs, and mRNAs encoding ribosomal proteins; these
showed a marked reduction in c-Myc mutant glands.
Thus, c-Myc is needed for efficient Pol I, II and III tran-
scription in the mammary gland. Since ribosome availa-
bility is the rate-limiting step in protein synthesis [68], the
strong decrease in the RNA level of components needed
for ribosome biogenesis, combined with others important
for translation, very likely explains the reduced milk pro-
duction in the c-Myc mutant glands. Although we did not
examine cell size in the mammary gland, it is possible that
the reduced biosynthetic activity could also result in
smaller cells, as c-Myc regulates cell size in some models/
organs analyzed [25,26,31,69]. It will be interesting to
address this aspect in detail in future studies.
Hormonal induction of milk production during lactation
is subject to transcriptional and translational control
mechanisms (reviewed in Rhoads and Grudzien-Nogalska
[70], Rosen et al. [71]); the latter have been extensively
studied using polysome fractionation techniques [72,73].
Here we show that c-Myc has a general role in translation
efficiency, as attested to by the reduction in the average
size of the polysomes in its absence; however, some selec-
tivity was also uncovered. While mRNA transcripts of milk
proteins (Lalba and Csn2) and enzymes important for
milk production (Fads2, Scd2, Elovl1, and Aldo3) were
shifted to smaller polysomes in c-Myc mutant glands,
other mRNAs were not affected. Indeed, there was little or
no change in the ribosome loading of β-actin, CK18, and
GAPDH mRNAs in the absence of c-Myc, suggesting that
their translation efficiency is not altered. It is well estab-
lished that different categories of mRNAs, referred to as
'weak' and 'strong', have diverse responses to general
changes in translation [74] and mRNAs for house-keeping
proteins are the least affected by external stimuli. Thus,
one plausible mechanism underlying the translational
selectivity could be that during lactation, a time when the
energy of the organ is devoted to milk production, targets
upregulated during the differentiation program would be
most affected by the limited availability of ribosomes,
while other mRNAs continue to be translated with con-
stant ribosome occupation. Finally, a recent study showed
that c-Myc stimulates translation by enhancing mRNA cap
methylation and subsequent ribosomal loading [13]. This
mechanism might also contribute to the selectivity that
we uncovered in the mammary gland. In conclusion, we
show here that c-Myc-deficient glands have reduced levels
of ribosomal proteins and RNA, as well as proteins
involved in ribosome biogenesis and translation. There-
fore, by acting on many different components of the
translation machinery, c-Myc has an important role in
successful and efficient translation during lactation.
Role of c-Myc in progenitor cell proliferation/survival
The role of c-Myc in stem and progenitor cells has been
intensively studied in different mouse models. In the
bone marrow, two reports showed that loss of c-Myc leads
to an accumulation of hematopoietic stem cells and a
severe loss of the committed lineages due to impaired dif-
ferentiation [32,34]. Moreover, elimination of both c-Myc
and N-Myc in hematopoietic stem cells impairs self-
renewal and leads to rapid apoptosis of stem cells [33]. In
the skin, depletion of the epidermal stem cell population,
due to insufficient amplification of the cells was observed
following c-Myc deletion [25]. A function for c-Myc in
mammary stem or progenitor cells seems likely, as the
Wnt and Notch signaling pathways are believed to play
important roles in mammary stem cells [75], and both
can directly stimulate c-Myc expression [76].
Indeed, our results suggest that c-Myc plays a role in a sub-
set of mammary gland progenitor cells, the Pi-MECs. This
population of WAPiCre expressing cells does not undergo
a secretory fate, but survives lactation and involution
[51,52]. A model of the mammary stem cell hierarchy sug-
gests that the Pi-MECs are contained in the Sca-1 negative
population and function as alveolar progenitors duringBMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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pregnancy [77]. As c-Myc mutant glands show a reduced
number of alveoli in the second pregnancy/lactation, it is
likely that fewer progenitor cells were present following c-
Myc loss in the first pregnancy and lactation. This hypoth-
esis is further supported by results from the transplanta-
tion experiments. The reduced outgrowth capacity found
with the mutant epithelium suggests that alveolar progen-
itors have an impaired ability to proliferate or to survive
in the absence of c-Myc.
Relevance of c-Myc in cancer
The importance of c-Myc in cancer was established more
than 20 years ago and much effort has gone into studying
all aspects of oncogenic c-Myc (reviewed in Meyer and
Penn [55]). c-Myc is aberrantly expressed in most breast
cancers as a result of gene amplification or from altera-
tions in signaling pathways that impact on c-Myc RNA or
protein levels. Myc and many of its target genes were
recently shown to be strongly expressed in basal, ERα neg-
ative breast tumors, allowing them to proliferate in the
absence of estradiol-induced signaling [78]. Our studies
on c-Myc in normal development have important impli-
cations for breast cancer. Indeed, it was shown in a c-Myc-
induced tumor model that Myc's ability to increase pro-
tein synthesis was a major factor contributing to aberrant
growth and genomic lesions [79].
Despite the phenotypes in pregnancy and lactation, the
effects of c-Myc loss in the mammary gland are generally
well tolerated, which is of interest considering c-Myc as a
target in cancer therapy [14,80]. Recent studies have eval-
uated the role of c-Myc in tumor onset and maintenance
and have also addressed side effects of Myc-targeting. In
the intestines, where inactivation of adenomatous poly-
posis coli (APC) is a key event in colorectal cancer devel-
opment, c-Myc is frequently overexpressed as a
downstream β-catenin/T cell factor target. Interfering with
c-Myc levels in mouse models with APC mutations res-
cued the observed phenotypes, leading to a reduction in
tumor burden and increased survival [81,82]. Further-
more, by employing an inducible, dimerization-interfer-
ing Myc construct in a Ras-induced lung adenocarcinoma
model, it was shown that Myc inhibition impaired tumor
maintenance. Importantly, the 'side-effects' observed in
other organs disappeared rapidly after cessation of Myc
inhibition [83]. Finally in Notch1-induced mammary
tumors it was shown that ablation of c-Myc reduces tumor
incidence and increases tumor latency, suggesting that
Myc might be an attractive target in cancers with deregu-
lated Notch signaling [36]. Multiple signal transduction
pathways activate c-Myc [84], many of which are deregu-
lated in breast cancer [85-87]. Future studies using differ-
ent mammary tumor models will provide more insight
into the role of c-Myc in tumor development and mainte-
nance, and in its potential as a breast cancer target.
Conclusion
Our data revealed three interesting new roles for c-Myc in
the mouse mammary gland. At the start of pregnancy, c-
Myc loss resulted in delayed proliferative response and
differentiation. During lactation, mutant glands showed
reduced milk production and slower pup weight-gain.
Furthermore, c-Myc-deficient glands were generally
impaired in translation efficiency and displayed reduced
levels of ribosomal RNA and proteins. Finally, the results
from transplantation assays suggest that c-Myc has a role
in progenitor cell proliferation and/or survival. Our
results provide new insight into Myc's physiological role
in breast development, which might gain special impor-
tance considering c-Myc as a novel target in the aggressive
basal breast cancer subtype.
Methods
Mouse strains
c-mycfl/fl mice were mated with mice containing a single
copy of the WAPiCre transgene and pups were further
intercrossed. Littermates with the genotype c-mycfl/fl;WAP-
iCre-  or  c-mycfl/+;WAPiCre-  (referred to as WT), c-mycfl/
fl;WAPiCre+  (mutant) and c-mycfl/+;WAPiCre+  (hetero-
zygous) were used for all studies. Mothers were main-
tained with litters of six pups and only inguinal glands
were taken in the experiments. For growth analysis, new-
born pups were mixed and two to seven pups were placed
with WT and mutant mothers. Body weight of each pup
was measured regularly and the results presented as aver-
age weight ± standard deviation. For milk volume experi-
ments, mothers were either directly sacrificed or after a 2
hour period without pups, to allow milk filling of the
gland. For milking females, pups were removed from
mothers for at least 4 hours, then mice were anaesthetized
with Ketarom (100 μl/10 g body weight intraperitoneal)
and milk release was induced by intraperitoneal injection
of 0.3 IU oxytocin. Milk was removed by applying gentle
pressure and directly drawing it into capillary tubes or
pipettes for further analysis. All animal experiments were
carried out under the Swiss guidelines for animal safety.
DNA/RNA isolation, PCR and RT-PCR
Pieces of mammary glands were flash frozen in liquid
nitrogen for RNA or DNA isolation. DNA was precipitated
with ethanol after proteinase K digestion (56°C over-
night). For detection of the recombined c-myc allele, the
following primers were used in a PCR: fw: 5'-AAATAGT-
GATCGTAG-TAAAATTTAGCCTG-3'; rw: 5'-TACAGTCCC-
AAAGCCCCAGCCAAG-3'. RNA was prepared using TRI-
zol reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer's instructions. Reverse transcription was
carried out using the Ready-To-Go You-Prime First-Strand
Beads (GE Healthcare, Buckinghamshire, UK) with
oligo(dT) 15 or random hexamer primers (both Promega,
Madison, WI, USA) for mRNA or rRNA detection, respec-
tively. We used 2 μl and/or 4 μl cDNA for semi-quantita-BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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tive PCR analysis. Detailed information (including
primers for semi- and quantitative PCR) can be found in
Additional file 2.
Milk analysis
Aliquots of milk were centrifuged in capillary tubes (30
minutes, 3,500 rpm) to determine the fat content (cream-
atocrit), measured as the ratio of the upper cream layer
length over total milk length [42]. Milk protein composi-
tion was analyzed by diluting fresh milk 1:20 in phos-
phate-buffered saline (PBS) and loading 5 μl and 10 μl on
15% SDS-PAGE, which was stained with Coomassie Blue.
For measuring lactose content, samples of milk, frozen in
liquid nitrogen and stored at -80°C, were thawed and cen-
trifuged (20 minutes, 4°C, 3,000 g) and 10 μl of the lower
aqueous phase were used in a colorimetric galactose/lac-
tose assay-kit (BioVision, Mountain View, CA, USA).
Immunohistochemistry
For histological examination, the central region of
inguinal mammary glands containing the lymph node
was used. Glands were fixed in freshly prepared 4% para-
formaldehyde in PBS and stored in 70% ethanol until
embedding in paraffin. IHC was performed on 4 μm par-
affin sections using the following antibodies: Cre [35],
CK18 (Progen Biotechnik, Heidelberg, Germany), c-Myc
(Upstate Biotechnology, 06-340, Lake Placid, NY, USA),
Ki-67 (Lab Vision, Fremont, CA, USA), cyclin D1 (Cell
Marque, Rocklin, CA, USA) and rabbit anti-milk serum
[41]. Stainings were carried out with the Discovery XT
Staining Module (Ventana Medical Systems SA, Stras-
bourg, France). Images were acquired with a Leica
DFC420 camera on a Nikon Eclipse E600 microscope
using Plan Fluor 10×/0.3, 20×/0.5, and 40×/0.75 lenses.
When necessary, optimization of brightness and contrast
was performed by standard procedures in Corel DRAW 13
and always applied equally to the whole set of images.
Mammary gland whole mounts and electron microscopy
For whole mount staining, inguinal glands were spread on
glass slides, fixed overnight at 4°C in Tellyesniczky's fixa-
tive and stained with iron-hematoxylin as described http:/
/www.bcm.edu/rosenlab. Images were captured by a Leica
DFC420 camera on a Nikon Eclipse E600 microscope
with a Plan Apo 4×/0.2 lens in the milk-filling experi-
ments. Pictures of other whole mounts and transplants
were taken on a Leica Z6 APO A microscope with a Plan
Apo 2.0× lens and a Leica DFC480 camera.
For electron microscopy, pieces of mammary gland were
fixed in Karnovsky's fixative (3% paraformaldehyde, 0.5%
glutaraldehyde in 10 mM PBS pH 7.4), washed, and post-
fixed in 1% OsO4. After dehydration with graded series of
ethanol, samples were embedded in Epon and sections of
60 to 70 nm thickness were cut. Sections were double
stained with uranyl acetate and lead acetate [88] and
viewed in a FEI Morgagni 268D transmission electron
microscope.
Image analysis and statistics
Images were taken with a Mirax Slidescanner (Zeiss AG,
Zurich, Switzerland) using a 20×/0.5 lens (0.2 μm/pixel)
and converted into standard TIFF format. Manual count-
ing of alveoli and measurement of alveolar areas were per-
formed on TIFF-files using the measurement module of
ImageAccess (Imagic AG, Glattbrugg, Switzerland). For
automatic detection and measurement of alveolar area
versus total organ area, images taken with the same slides-
canner were analyzed using Definiens Software (Defin-
iens AG, Munich, Germany).
Statistical analysis for alveolar area quantification and
pup weight analysis was performed with one-sided Stu-
dent's t-test. For alveolar counts, the ratios of the numbers
obtained from mutant versus corresponding WT litter-
mate were tested for significant deviation from one using
'one sample' t-test.
Lysate preparation and Western blot analysis
Frozen pieces of mammary gland were ground to powder
in liquid nitrogen and homogenized in RIPA buffer (50
mM Tris pH8, 1% NP40, 0.5% sodium deoxycholate,
20% SDS, 150 mM NaCl) complemented with 5 mM eth-
ylene glycol tetraacetic acid, 1 mM dithiothreitol (DTT),
20 mM sodium pyrophosphate, 10 μg/ml aprotinin, 10
μg/ml leupeptin, 0.5 mM phenylmethanesulfonylfluoride
(PMSF) and 1 mM sodium orthovanadate. Lysates were
subjected to SDS-PAGE and transferred to polyvinylidene
fluoride membranes (Millipore, Bedford, MA, USA). After
blocking, membranes were incubated overnight at 4°C
with primary antibodies against α-tubulin (Neomarkers,
Fremont, CA, USA) and β-casein [89], or 1 hour at RT with
rabbit anti-milk serum [41]. Signals were detected by
using horseradish peroxidase-linked secondary antibodies
(GE Healthcare) and enhanced chemiluminescent detec-
tion reagent (GE Healthcare).
Polysome fractionation of mammary glands and livers
Half of an inguinal mammary gland and a piece of liver
(both approximately 80 to 120 mg) were flash frozen in liq-
uid nitrogen. For extract preparation, tissue was ground to a
white homogeneous powder in liquid nitrogen with 1 ml
polysome buffer (10 mM Tris pH8, 150 mM NaCl, 5 mM
MgCl2, 1% NP-40, 1% DOC, 10 mM DTT, 50 μg/ml
cycloheximide, 0.4 U/μl RNAsin, 1 mM PMSF, 20 μg/ml
aprotinin and leupeptin, supplemented with complete pro-
tease inhibitor (Roche Diagnostics, Indianapolis, IN, USA)).
After thawing, cell debris were removed by centrifugation
(12,000 g, 10 minutes, 4°C) and 700 μl of supernatant were
loaded on to a linear sucrose gradient (15% to 60% sucrose
(w/v), in 10 mM Tris pH 7.5, 140 mM NaCl, 1.5 mM MgCl2,
10 mM DTT, 100 μg/ml cycloheximide). Gradients were cen-BMC Biology 2009, 7:63 http://www.biomedcentral.com/1741-7007/7/63
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trifuged in a SW41Ti rotor (Beckman Coulter Inc., Fullerton,
CA, USA) for 2 hours at 38,000 rpm at 4°C with brakes off.
Twelve fractions of 0.5 ml were collected as previously
described [90]. RNA was isolated using TriZol reagent as
described above: 1 μl glycogen (20 mg/ml) was added to
facilitate isopropanol precipitation of RNA.
Transplantation of mammary epithelium into cleared fat 
pads of NOD/SCID recipients
Inguinal mammary glands of 3- to 4-week-old NOD/SCID
mice (body weight below 13 g) were cleared of endogenous
mammary epithelium as described [91]. Donor epithelium
was derived from mammary glands of day 5.5 lactating WT
and mutant mothers and chopped into approximately 1
mm3 pieces. Outgrowth efficiency was monitored 8 weeks
after transplantation by sacrificing non-pregnant recipients
and staining mammary gland whole mounts as described
above. Transplants were scored as successful when originat-
ing from a central part of the cleared gland with ducts grow-
ing in all directions [92]. Positive outgrowths were rated as
'+' (filling <25% of the gland), '+ +' (filling 25% to 50%) and
'+ + +' (filling about 75%).
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